ACC 2021 Prof. Chew summarizes the 12-months follow-up findings of the rapid TnT trial comparing two protocols of hs-troponin in patients with suspected ACS. He also gives his interpretation of the results.
As an author of a Clinical Review in European Heart Journal, Niels van der Sangen discusses the options for a personalized approach of antithrombotic therapy after PCI, as described in the paper.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.
ACC 2020 Prof. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study).
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.
CSI Paris Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.
CSI Paris Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.
Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.
ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.
ESC 2019 Based on data of the COMPLETE trial, prof. Mehta answers the questions whether routine complete revascularization vs. culprit lesion only PCI can change cardiac outcomes and disease course, and whether it should become standard practice for patients with STEMI.
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.
ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.
ESC 2019 Prof. Stewart investigated two protocols for oxygen administration in 40,000 patients with ischemic symptoms in New-Zealand. In most, oxygen gives no advantages and no disadvantages, but a subgroup may benefit from oxygen.
ESC 2019 Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.
ESC 2019 Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.
ESC 2019 Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduced ischemic endpoints as compared with ticagrelor, without an increased bleeding risk.
ESC 2019 In patients with suspected ACS, adoption of an early rule-out pathway for MI using hs-troponin reduced the length of stay, increased proportion of patients discharged by emergency department and was safe.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.
ESC 2018 Results of the VERDICT trial were neutral for an early intervention strategy compared to standard management in NSTEMI patients. However, a beneficial effect of early intervention was observed in those with a GRACE score >140.
ESC 2018 Prof. Serruys gives a brief overview of the study design and results of the GLOBAL LEADERS trial in patients post-ACS and with stable angina.
ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.
ESC 2016 Dr. Ik-Kyuang Jang shares the insights gained from a pilot study that tested a new therapeutic approach in patients with ACS induced by plaque erosion, namely to give drug therapy instead of placing a stent.
ESC 2016 The ANTARCTIC study tested the hypothesis that measuring platelet function would improve outcome in high-risk patients after ACS. Stefan Gielen discusses the surprising finding that this approach has no value in clinical practice.
ESC 2016 The PRAGUE-18 study was a direct comparison between the potent P2Y12 inhibitors prasugrel and ticagrelor. While the study was stopped early due to futility, Steen Dalby Kristensen thinks that there is no major difference between the two agents.
Erik Stroes, MD, explains why further LDL-C lowering therapies are needed and what is the potential role of PCSK9-inhibitors in ACS patients.
Peter Libby considers how the pathophysiology of atherosclerosis and the mechanisms of ACS are changing, as a result of preventive therapies and a change in risk factors, toward superficial erosion.
Prof. Peter Libby (Boston, MA, USA) discusses how views on mechanisms of ACS have changed over time and how traditional thoughts on plaque composition and vulnerability are now challenged. He proposes a new mechanism of coronary thrombosis that may cause ACS.
A mechanism of action video on the potential role of inflammation in atherothrombosis
Prof. Paul Ridker sets out how the hypothesised role for inflammation in atherosclerosis is now a pathway that can be targeted therapeutically. He consideres ongoing efforts to target the inflammatory response.
Professor Raffaele de Caterina shows that thrombosis is not only the indirect result of atherosclerosis, but can also be induced by inflammation directly.
ISA 2015 Prof. Peter Libby recapitulates evolving insights into the mechanism of acute coronary syndromes, and how we may be shifting from a predominance of plaque ruptures towards superficial erosion as the cause of ACS.
Prof Peter Libby, Boston, USA, discusses the implications of recent insights in inflammation in atherosclerosis with Göran Hansson, Stephen Nicholls and Paul Ridker.
Prof. Kausik Ray, London updates on novel research in the field of HDL-mimetics targeting the unstable plague in post ACS patients
Peter Sinnaeve, MD UZ Leuven discussing new registries on ACS/PCI: how does the real world look like, as part of an EBAC accredited educational programme held during ESC 2014
Prof. Petr Widimsky, Prague, Czech Republic discussing the latest guidelines on ACS/PCI: what are the key changes?, as part of an EBAC accredited educational programme held during ESC 2014
Prof. Peter Sinnaeve, MD UZ Leuven, Leuven, discussing an ACS/PCI patient case based on real world data, as part of an EBAC accredited educational programme ACS management 2014held during ESC 2014
Prof. Petr Widimsky, Prague, Czech Republic discussing an ACS/PCI patient case based on latest guidelines, as part of an EBAC accredited educational programme held during ESC 2014
Raphael Duivenvoorden, Amsterdam, describes an innovative nanotechnique to reduce the risk of a recurrent myocard infarct, in which inflammation is a key factor.